The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of matrix metalloproteinase 2 (MMP2) baseline plasma level to objective response (OR), progression free survival (PFS), and overall survival (OS) and changes under treatment in patients treated with bevacizumab (Bev) for recurrent high-grade glioma (HGG).
Emeline Tabouret
No relevant relationships to disclose
Francoise Boudouresque
No relevant relationships to disclose
Jaime Callego Perez-Larraya
No relevant relationships to disclose
Maryline Barrie
No relevant relationships to disclose
Giuseppe Lombardi
No relevant relationships to disclose
Mona Matta
No relevant relationships to disclose
Anna Luisa Di Stefano
No relevant relationships to disclose
Marianne Labussiere
No relevant relationships to disclose
Celine Boucard
No relevant relationships to disclose
Anderson Loundou
No relevant relationships to disclose
Sylvie Romain
No relevant relationships to disclose
Antoine F Carpentier
Honoraria - Roche
Marc Sanson
Honoraria - Roche
L'houcine Ouafik
No relevant relationships to disclose
Oliver L. Chinot
Consultant or Advisory Role - Roche